- News Releases
ROCHESTER, Minn. — Treating transplant patients with mild to moderate cases of COVID-19 with monoclonal antibodies is safe and helps prevent serious illness, according to a Mayo Clinic study recently published in Open Forum Infectious Diseases. These results are especially important because transplant patients who are infected with COVID-19 have a higher risk of severe illness and death.
"Monoclonal antibody therapy is really important for the transplant population because they are less likely to develop their own immunity. Providing them with these antibodies helps them recover from COVID-19," says Raymund Razonable, M.D., a Mayo Clinic infectious diseases specialist and the study's senior author.
The retrospective study focused on the first 73 solid organ transplant patients who received monoclonal antibody infusions for treatment of mild to moderate COVID-19 between Nov. 19, 2020, and Jan. 23 at Mayo Clinic. Eleven patients had an emergency department visit and nine patients were hospitalized. Most significantly, no patients required mechanical ventilation, died or experienced organ rejection.
"While we expected monoclonal antibody therapy would be beneficial for patients, we were pleasantly surprised by the results. Only one patient required care in the ICU for non-COVID-19 indication, and, most importantly, there were no deaths," Dr. Razonable says.
Monoclonal antibodies help prevent the virus that causes COVID-19 from attaching to human cells, which helps block the spread of infection. In fall 2020, the Food and Drug Administration authorized the emergency use of bamlanivimab and casirivimab-imdevimab to treat mild to moderate COVID-19 in patients with a high risk of becoming seriously ill. But since the safety and efficacy of these therapies for transplant patients remained unknown due to the limited clinical data, many health care institutions initially hesitated to set up infusion centers, Dr. Razonable says.
The study's results highlight the important role monoclonal antibodies can play in treating transplant patients with mild to moderate COVID-19. Knowing how best to treat these patients remains crucial given that recent studies indicate that COVID-19 vaccines are not as effective for transplant patients.
"It is important that these patients have early access to monoclonal antibody treatment," Dr. Razonable says. "Our data show the outcomes for patients are better if they get infused earlier." The study's lead author is Zachary Yetmar, M.D., Mayo Clinic. Other co-authors are Elena Beam, M.D.; Jack O'Horo, M.D.; Ravindra Ganesh, M.B.B.S., M.D.; Dennis Bierle, M.D.; Lisa Brumble, M.D.; and Teresa Seville, M.D. ― all of Mayo Clinic.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. For information on COVID-19, including Mayo Clinic's Coronavirus Map tracking tool, which has 14-day forecasting on COVID-19 trends, visit the Mayo Clinic COVID-19 Resource Center.
For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was either recorded prior to COVID-19 or recorded in a nonpatient care area where social distancing and other safety protocols were followed.
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.
For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.
Learn more about tracking COVID-19 and COVID-19 trends.
ROCHESTER, Minn. — According to a new study published by Mayo Clinic researchers, the COVID-19 pandemic was linked to a 17% increase in the death ...
According to the Centers for Disease Control and Prevention (CDC), routine vaccinations for kindergarten in the U.S. fell to 93% during the 2021-2022 school year. That's ...
Flu cases and respiratory syncytial virus (RSV) rates are beginning to drop in the U.S.; however, reported cases of COVID-19 are increasing. A new COVID-19 omicron variant, XBB.1.5, is spreading quickly and ...